Cai-Zhong Chen1,2, Sheng-Xiang Rao3,4, Ying Ding5,6, Shu-Jie Zhang7,8, Feng Li9, Qiang Gao10, Meng-Su Zeng11,12. 1. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. chen.caizhong@zs-hospital.sh.cn. 2. Shanghai Medical Imaging Institute, 180 Fenglin Rd, Shanghai, 200032, China. chen.caizhong@zs-hospital.sh.cn. 3. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. rao.shengxiang@zs-hospital.sh.cn. 4. Shanghai Medical Imaging Institute, 180 Fenglin Rd, Shanghai, 200032, China. rao.shengxiang@zs-hospital.sh.cn. 5. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. ding.ying@zs-hospital.sh.cn. 6. Shanghai Medical Imaging Institute, 180 Fenglin Rd, Shanghai, 200032, China. ding.ying@zs-hospital.sh.cn. 7. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. zhang.shujie@zs-hospital.sh.cn. 8. Shanghai Medical Imaging Institute, 180 Fenglin Rd, Shanghai, 200032, China. zhang.shujie@zs-hospital.sh.cn. 9. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. li.feng2@zs-hospital.sh.cn. 10. Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. gao.qiang@zs-hospital.sh.cn. 11. Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. zengmengsu@126.com. 12. Shanghai Medical Imaging Institute, 180 Fenglin Rd, Shanghai, 200032, China. zengmengsu@126.com.
Abstract
PURPOSE: To evaluate the differences in enhancement pattern of hepatocellular carcinoma (HCC) 20 mm or smaller and enhancement effects of hepatic vessels on early dynamic contrast-enhanced magnetic resonance imaging (MRI) obtained with gadoxetic acid and gadopentetate dimeglumine in the same patients with cirrhosis. METHODS: We reviewed MR images using gadoxetic acid and gadopentetate dimeglumine in the same 34 patients with 42 histologically confirmed HCCs (median diameter, 14.5 mm). The percentage enhancements (PEs) of HCC, the hepatic artery and portal vein and relative contrasts (RCs) between HCC and the liver were calculated and analyzed statistically. RESULTS: The PEs of HCC, the hepatic artery and portal vein were significantly lower for gadoxetic acid in comparison with gadopentetate dimeglumine in the arterial phase (p = 0.0256 for HCC, p < 0.0001 for hepatic artery) and portal phase (p < 0.0001 for HCC, portal vein). The RC between HCC and the liver was significantly lower for gadoxetic acid in comparison with gadopentetate dimeglumine in the arterial phase (p = 0.0422), but was not significantly different in the portal phase (p = 0.1133). Forty-one of the 42 (97.62 %) nodules showed arterial hypervascularization. Of these, 31 (75.61 %) nodules were hypointense in the portal phase for gadoxetic acid, and 22 (53.66 %) were hypointense for gadopentetate dimeglumine (p = 0.038). CONCLUSIONS: Compared with gadopentetate dimeglumine, gadoxetic acid-enhanced MRI demonstrated a different enhancement pattern of inferior arterial enhancement and was more rapidly hypointense in the portal phase for HCC. It showed markedly lower enhancement for hepatic artery and portal vein in the patients with cirrhosis.
PURPOSE: To evaluate the differences in enhancement pattern of hepatocellular carcinoma (HCC) 20 mm or smaller and enhancement effects of hepatic vessels on early dynamic contrast-enhanced magnetic resonance imaging (MRI) obtained with gadoxetic acid and gadopentetate dimeglumine in the same patients with cirrhosis. METHODS: We reviewed MR images using gadoxetic acid and gadopentetate dimeglumine in the same 34 patients with 42 histologically confirmed HCCs (median diameter, 14.5 mm). The percentage enhancements (PEs) of HCC, the hepatic artery and portal vein and relative contrasts (RCs) between HCC and the liver were calculated and analyzed statistically. RESULTS: The PEs of HCC, the hepatic artery and portal vein were significantly lower for gadoxetic acid in comparison with gadopentetate dimeglumine in the arterial phase (p = 0.0256 for HCC, p < 0.0001 for hepatic artery) and portal phase (p < 0.0001 for HCC, portal vein). The RC between HCC and the liver was significantly lower for gadoxetic acid in comparison with gadopentetate dimeglumine in the arterial phase (p = 0.0422), but was not significantly different in the portal phase (p = 0.1133). Forty-one of the 42 (97.62 %) nodules showed arterial hypervascularization. Of these, 31 (75.61 %) nodules were hypointense in the portal phase for gadoxetic acid, and 22 (53.66 %) were hypointense for gadopentetate dimeglumine (p = 0.038). CONCLUSIONS: Compared with gadopentetate dimeglumine, gadoxetic acid-enhanced MRI demonstrated a different enhancement pattern of inferior arterial enhancement and was more rapidly hypointense in the portal phase for HCC. It showed markedly lower enhancement for hepatic artery and portal vein in the patients with cirrhosis.
Authors: Konstantin Nikolaou; Stefan O Schoenberg; Gunnar Brix; Jeffrey P Goldman; Ulrike Attenberger; Bernd Kuehn; Olaf Dietrich; Maximilian F Reiser Journal: Invest Radiol Date: 2004-09 Impact factor: 6.016
Authors: Martin Rohrer; Hans Bauer; Jan Mintorovitch; Martin Requardt; Hanns-Joachim Weinmann Journal: Invest Radiol Date: 2005-11 Impact factor: 6.016
Authors: K Ito; D G Mitchell; H W Hann; Y Kim; T Fujita; H Okazaki; K Honjo; N Matsunaga Journal: AJR Am J Roentgenol Date: 1999-09 Impact factor: 3.959